If Your Portfolio Is Down on the Tariff News, Check Out This Little-Known High-Yield Dividend Stock

Market Overview - Investors are currently selling growth stocks due to new tariff policies, leading to a decline of approximately 10% in the S&P 500 and Nasdaq Composite since April 2, 2023 [1][2]. Company Profile: Kenvue - Kenvue was spun off from Johnson & Johnson in 2023 and represents J&J's consumer health portfolio, including well-known brands like Listerine, Neutrogena, and Tylenol [5][6]. Investment Thesis for Kenvue - Despite potential supply chain disruptions from tariffs, Kenvue is viewed as a good investment opportunity due to its portfolio of consumer staple products that are essential regardless of economic conditions [6][7]. - Kenvue's products tend to have inelastic demand, meaning consumers are likely to continue purchasing trusted brands even if prices rise [8]. - Kenvue is not classified as a growth stock, but it is positioned for stability and potential growth amid market fluctuations, making it a prudent choice for investors [9][10]. Financial Metrics - Kenvue offers an attractive dividend yield of 3.7%, which is nearly three times the yield of the SPDR S&P 500 ETF Trust, providing a compelling case for dividend investors [10][11].